drugset
drugset / Trial / NCT01602393

Evaluation of Safety & Tolerability of Multiple Dose Regimens of CHF 5074 and Exploration of Effects on Potential Markers of Clinical Efficacy in Patients With Mild Cognitive Impairment - Prolonged Open Label Extension Phase

NCT01602393 ↗

Phase 2 Completed 51 enrolled Chiesi Farmaceutici S.p.A.
Non-randomizedParallel-groupOpen-labelTreatment

Summary

The purpose of the study is to evaluate the safety and tolerability of ascending oral doses of CHF 5074 after prolonged administration to patients with mild cognitive impairment.

Timeline

Start
2012-05
Primary completion
2013-10
Completion
2013-10

Drugs

EvaluationDrugModalityDoseRoute
Subject CHF 5074 Unknown 200 mg Oral
Subject CHF 5074 Unknown 400 mg Oral
Subject CHF 5074 Unknown 600 mg Oral

Indications

Alzheimer disease